Literature DB >> 21683810

Gel-based proteomics of liver cancer progression in rat.

Jakob Albrethsen1, Leah M Miller, Phyllis M Novikoff, Ruth H Angeletti.   

Abstract

A significant challenge in proteomics biomarker research is to identify the changes that are of highest diagnostic interest, among the many unspecific aberrations associated with disease burden and inflammation. In the present study liver tissue specimens (n=18) from six experimental stages were collected from the resistant hepatocyte (RH) rat model of liver cancer and analyzed by 2D DIGE. The study included triplicates of regenerating liver, control "sham-operated" liver, three distinct premalignant stages and hepatomas. Out of 81 identified proteins two-thirds were differentially abundant in rat hepatomas compared to control rat liver and, secondly, the majority of proteins were also changed in precursor stages. This underscores the importance of adequate control samples in explorative cancer biomarker research. We confirm several proteomic changes previously identified in human hepatocellular carcinoma (HCC) and we identify novel candidate proteomic aberrations for further analysis in human HCC. In particular, increased levels of HSP70, HSP90, AKR1B1, AKR7A3, GCLM, ANXA5, VDBP, RGN and SULT1E1 were associated specifically with rat hepatomas, or with liver cancer progression in rat. In addition, we examine an integrated gel-based workflow for analysis of protein post-translational modifications (PTMs) and microtubule-association. We highlight differential PTM and localization of HSP60 as an interesting target for further analysis in liver cancer.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683810     DOI: 10.1016/j.bbapap.2011.05.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Proteomics of cancer cell lines resistant to microtubule-stabilizing agents.

Authors:  Jakob Albrethsen; Ruth H Angeletti; Susan Band Horwitz; Chia-Ping Huang Yang
Journal:  Mol Cancer Ther       Date:  2013-11-19       Impact factor: 6.261

2.  Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers.

Authors:  Caroline Lambrecht; Gabriela Bomfim Ferreira; Judit DomÈnech Omella; Louis Libbrecht; Rita DE Vos; Rita Derua; Chantal Mathieu; Lut Overbergh; Etienne Waelkens; Veerle Janssens
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

Review 3.  Proteome Analyses of Hepatocellular Carcinoma.

Authors:  Dominik A Megger; Wael Naboulsi; Helmut E Meyer; Barbara Sitek
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

Review 4.  Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.

Authors:  Reza Khayami; Seyyed Reza Hashemi; Mohammad Amin Kerachian
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

5.  Evaluation of toxicogenomics approaches for assessing the risk of nongenotoxic carcinogenicity in rat liver.

Authors:  Johannes Eichner; Clemens Wrzodek; Michael Römer; Heidrun Ellinger-Ziegelbauer; Andreas Zell
Journal:  PLoS One       Date:  2014-05-14       Impact factor: 3.240

6.  Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells.

Authors:  Chang-Cheng Zhao; Wen-Wei Yu; Ying-Jie Qi; Liang-Fei Xu; Zi-Ran Wang; Ya-Wen Qiang; Fan Ma; Xiao-Ling Ma
Journal:  Anticancer Drugs       Date:  2020-03       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.